MedTrace Logo

Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-779788 in Healthy Subjects

NCT00836602 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2011-02-23

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the safety and tolerability of multiple oral doses of BMS-779788 in healthy subjects

Conditions

Interventions

DRUG

BMS-779788

Oral Solution, Oral, 1 mg, Once daily, 7 days

DRUG

BMS-779788

Oral Solution, Oral, 2 mg, Once daily, 7 days

DRUG

BMS-779788

Oral Solution, Oral, \<= 4 mg, Once daily, 7 days

DRUG

Placebo

Oral Solution, Oral, 0 mg, Once daily, 7 days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00836602 on ClinicalTrials.gov